TEL-AVIV, Israel, Jan. 04, 2017 (GLOBE NEWSWIRE) -- RedHill
Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a
specialty biopharmaceutical company primarily focused on the development and
commercialization of late clinical-stage, proprietary, orally-administered,
small molecule drugs for gastrointestinal and inflammatory diseases and cancer,
today announced that the underwriters of its previously announced underwritten
public offering of 2,250,000 American Depository Shares (“ADSs”), each
representing 10 of its ordinary shares, and warrants to purchase 1,125,000
ADSs, have partially exercised their option and purchased 133,104 ADSs.
Source :
RedHill Biopharma Ltd.
No comments:
Post a Comment